Development of mavoglurant and its potential for the treatment of fragile X syndrome-Reference-Cited by-同舟云学术

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Published:2013-11-20 Issue:1 Volume:23 Page:125-134
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Gomez-Mancilla Baltazar¹,Berry-Kravis Elizabeth²,Hagerman Randi³,von Raison Florian⁴,Apostol George⁴,Ufer Mike¹,Gasparini Fabrizio¹,Jacquemont Sébastien⁵

Affiliation:

1. Novartis Institutes for BioMedical Research Basel, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland ; ;

2. Rush University Medical Center, Departments of Pediatrics, Neurological Sciences, and Biochemistry, Chicago, IL 60612, USA

3. M.I.N.D. Institute and Department of Pediatrics, UC Davis Health System, Sacramento, CA 95817, USA

4. Novartis Pharma AG, Neuroscience Development, CH-4056 Basel, Switzerland

5. Service de Génétique Médicale, Centre Hospitalier Universitaire Vaudois, 2 Ave Pierre Decker, 1011 Lausanne, Switzerland

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.2014.857400

Reference57 articles.

1. X linked mental retardation.

2. Fragile X and autism: A multicenter survey

3. Molecular and cytogenetic analyses of autism in Taiwan

4. Cytogenetic abnormalities and fragile-x syndrome in Autism Spectrum Disorder

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiscale topology in interactomic network: from transcriptome to antiaddiction drug repurposing;Briefings in Bioinformatics;2024-01-22

2. Genodermatoses with behavioural sequelae;Postgraduate Medical Journal;2021-04-29

3. Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers;NeuroImage;2021-04

4. Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction;Current Pharmaceutical Design;2020-01-08

5. Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development;Medicinal Research Reviews;2019-02-10